evipedia.ai
← Back

Ipamorelin for Health & Longevity

Evidence Review created on 10/27/2026 using AI4L / Opus 5.5

Also known as: Ipamorelin Acetate, NNC 26-0161

Motivation

Ipamorelin is a small, lab-made chain of five amino acids, injected under the skin, that prompts the pituitary gland to release the body’s own growth hormone. Growth hormone output falls steadily with age, a decline that researchers have studied in relation to muscle, body fat and sleep. A compound that nudges the body to release more of its own hormone, rather than replacing it, therefore draws interest from people who want to age well.

Ipamorelin was created in the late 1990s as a drug candidate and was later studied in hospital patients recovering from bowel surgery. It is not an approved medicine. It has since found a second life in wellness clinics and online peptide markets, often paired with a related peptide, while drug regulators and sports anti-doping bodies have restricted its use.

This review examines what is known about ipamorelin’s effects on body composition, sleep and healthy aging, its short- and long-term risks, how it is used in practice, and how strong and independent the underlying evidence is.

Benefits - Risks - Protocol - Conclusion

The following items give high-level overviews of ipamorelin and the growth hormone-releasing peptide class it belongs to.

No content on ipamorelin was found from Rhonda Patrick, Chris Kresser or Lifespan.io: their site searches and web searches returned nothing on the compound, and the FoundMyFitness search page could not be rendered by any retrieval tool. Life Extension covers ipamorelin only in a one-paragraph subsection of its testosterone protocol (Life Extension Male Hormone Optimization protocol), too brief to serve as an overview.

Grokipedia

  • Ipamorelin

    An AI-written encyclopedia entry on ipamorelin’s chemistry, receptor action, history and regulatory status; its two-hour half-life (time for blood levels to halve) for under-the-skin injection extrapolates a figure measured after vein infusion.

Examine

No Examine article on ipamorelin exists. Examine.com covers dietary supplements and does not typically cover unapproved injectable peptides or prescription medications.

ConsumerLab

No ConsumerLab article on ipamorelin exists. ConsumerLab tests dietary supplements and does not typically cover injectable peptides or prescription medications.

Systematic Reviews

No systematic reviews or meta-analyses for Ipamorelin were found on PubMed as of October 27, 2026.

Neither ipamorelin’s claimed benefits nor its principal risks are therefore represented by a systematic review or meta-analysis; the reviews of injected growth hormone cited in later sections concern a different compound.

Mechanism of Action

Ipamorelin is a five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that activates the growth hormone secretagogue receptor type 1a (GHSR-1a), the receptor for ghrelin (a stomach hormone that signals hunger and triggers GH release) (Raun 1998).

  • Pituitary pulse: Receptor activation in the pituitary releases a burst of GH, which prompts the liver to make IGF-1. Because the body’s brakes stay intact (somatostatin, a hormone that switches GH release off, and IGF-1 feedback), levels rise in pulses rather than continuously, unlike injected GH (Dominikowski 2026).
  • Selectivity: In pigs, ipamorelin did not raise adrenocorticotropic hormone (ACTH, the pituitary signal for cortisol) or cortisol, even at doses 200-fold above its effective dose, unlike the older GH-releasing peptides GHRP-2 and GHRP-6; none of the three raised prolactin (Raun 1998). Human data on selectivity are sparse.
  • Pharmacokinetics (how the body handles it): In healthy men given intravenous (into a vein) infusions, the half-life was 2 hours and the volume of distribution (how widely it spreads into tissues) was 0.22 L/kg, consistent with staying mainly in blood and fluid between cells; GH peaked about 40 minutes after dosing (Gobburu 1999).
  • Metabolism: In rats, 60–80% was excreted unchanged, mainly in urine, and nasal absorption reached about 20% (Johansen 1998, a Novo Nordisk study); no role for cytochrome P450 (CYP) liver enzymes has been described.
  • Competing view: Some effects bypass GH. Ipamorelin increased body fat even in GH-deficient mice, possibly through increased feeding (Lall 2001), and the same receptor in the gut speeds gut movement (Venkova 2009).

Historical Context & Evolution

  • Original purpose: Novo Nordisk chemists created ipamorelin while searching for a GH-releasing drug with fewer hormonal side effects than earlier peptides, describing it in 1998 as the first selective GH secretagogue (a drug that triggers the body’s own GH release) (Raun 1998). Their rat studies of faster bone growth were framed around children with growth failure (Johansen 1999).
  • Gut-motility program: Helsinn Therapeutics later tested intravenous ipamorelin for postoperative ileus (temporary stalling of the bowel after surgery). Its 117-patient phase 2 (mid-stage) trial found no significant speed-up in return to eating (Beck 2014), and a 320-patient dose-finding trial completed in 2014 without posted results (NCT01280344). No later-phase trial was registered.
  • Wellness adoption: Interest then shifted to healthy aging. Ipamorelin is promoted as a gentler alternative to injected GH that preserves the body’s own pulsing, and it is commonly paired with CJC-1295 (a lab-made analogue of growth hormone-releasing hormone, or GHRH, the brain signal that starts GH release) (Dominikowski 2026).
  • Regulatory turn: In September 2023 the U.S. Food and Drug Administration (FDA) placed ipamorelin acetate in Category 2, substances that may pose significant safety risks in compounding, citing immunogenicity (the risk of provoking an immune reaction) and deaths in the intravenous trial (FDA Category 2 list).
  • What changed: No new human trial has appeared since 2014. Shifts in opinion have been driven by regulators, practitioners and consumer demand rather than by new outcome data, so the scientific record still rests on 1990s pharmacology and one surgical trial.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no ipamorelin trial in any population has shown improvement in a clinical endpoint or validated surrogate, so no such outcome has been replicated by a second research group.

Medium 🟩 🟩

No benefit reaches Medium: the only controlled ipamorelin trial in people missed its primary outcome (Beck 2014), and the body-composition and sleep data come from a different compound, ibutamoren.

Low 🟩

Body Composition: More Lean Mass, Less Fat ⚠️ Conflicted

Indirect: no ipamorelin body-composition trial exists. Ibutamoren (MK-677, oral ghrelin-receptor drug) raised lean mass in healthy older adults without strength gain (Nass 2008, Merck co-authors). Ipamorelin preserved muscle in steroid-treated rats (Andersen 2001, Aagaard 2009) but increased fat in mice (Lall 2001). Net: modest lean gain plausible; fat loss unsupported.

Magnitude: Ibutamoren 25 mg daily (not ipamorelin) over 12 months: fat-free mass changed +1.1 kg [95% confidence interval [CI], the range likely to contain the true value, 0.7 to 1.5] vs −0.5 kg [95% CI, −1.1 to 0.2] with placebo, P<0.001 (P, the probability the difference arose by chance); total and visceral (around-organ) fat did not differ between groups (Nass 2008).

Deeper Sleep ⚠️ Conflicted

Deep sleep coincides with the main nightly GH pulse. No ipamorelin sleep study exists; ibutamoren lengthened deep and REM (rapid eye movement, dreaming) sleep in a small placebo-controlled trial (Copinschi 1997). Insomnia was more frequent with ipamorelin than placebo in the surgical trial (Beck 2014). Net: unproven for ipamorelin.

Magnitude: Ibutamoren 25 mg at bedtime (not ipamorelin): about 50% longer stage IV (deepest) sleep and over 20% more REM sleep than placebo in 8 young adults, P<0.05 (Copinschi 1997); intravenous ipamorelin after bowel surgery: insomnia 10.7% vs 5.2% with placebo, significance not reported (Beck 2014, figures as tabulated in FDA’s review on the FDA advisory committee page).

Faster Bowel Recovery After Surgery ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Ipamorelin sped gut transit after surgery in rats (Venkova 2009). In a 117-patient placebo-controlled trial of infusions into a vein, return to eating was not significantly faster (Beck 2014, Helsinn-sponsored); a 320-patient trial posted no results (NCT01280344). This bears on surgical recovery, not longevity. Net: human evidence is negative.

Magnitude: Median time to first tolerated meal 25.3 hours with ipamorelin vs 32.6 hours with placebo, P=0.15, not statistically significant (Beck 2014).

Speculative 🟨

Bone Growth and Bone Mineral

In rats, ipamorelin sped long-bone growth (Johansen 1999, Novo Nordisk), enlarged bones without raising density (Svensson 2000), and offset steroid-induced loss of bone formation (Andersen 2001). Basis is animal-only; no human bone data exist.

Restoring Youthful Growth Hormone Pulses

A single vein infusion raised GH dose-dependently in healthy men (Gobburu 1999); GH and IGF-1 levels are unvalidated stand-ins for health outcomes, and repeated dosing in older adults is untested. Basis is mechanistic.

Benefit-Modifying Factors

  • Genetic variants: No pharmacogenetic (gene-based drug response) data exist for ipamorelin. Variation in the GHSR gene (which encodes the ghrelin receptor) could plausibly alter response, but no study has tested this.
  • Baseline IGF-1: People with low-normal IGF-1 for their age have the most room for a rise; those already near the top of the age-adjusted range gain little and add risk. This is inferred from GH physiology; no ipamorelin data are stratified by IGF-1.
  • Sex: Oral estrogen (in contraceptives or menopausal hormone therapy) lowers the liver’s IGF-1 output per unit of GH, so women taking it may see a smaller IGF-1 response; inferred from physiology. No sex-specific ipamorelin data exist.
  • Pre-existing conditions: Ipamorelin works through the pituitary, so people with pituitary damage and true GH deficiency are expected to respond poorly. Obesity and high insulin blunt GH release and may also reduce response; both are inferred from mechanism.
  • Age: GH output falls with age, leaving a larger gap to close. In adults aged 60–81, ibutamoren restored young-adult GH and IGF-1 levels and raised lean mass, yet strength and function did not improve (Nass 2008).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: ipamorelin’s controlled adverse-event data come from a single trial by one sponsor, and the class-level harms come from other compounds.

Medium 🟥 🟥

No risk reaches Medium: that single trial used intravenous infusions in patients recovering from bowel surgery, a different route, dose and population from wellness use, so its signals count as indirect.

Low 🟥

Elevated Blood Sugar

Growth hormone opposes insulin. Hyperglycemia (high blood sugar) at discharge was more common with ipamorelin in the surgical trial (Beck 2014, Helsinn-sponsored), and ibutamoren raised fasting glucose and lowered insulin sensitivity in older adults (Nass 2008). Indirect: intravenous dosing after surgery, and another compound.

Magnitude: Hyperglycemia at discharge 14.3% with ipamorelin vs 8.6% with placebo, significance not reported (Beck 2014, figures as tabulated in FDA’s review on the FDA advisory committee page); fasting glucose rose 0.3 mmol/L (95% CI, 0.1 to 0.4; 5 mg/dL) with ibutamoren vs 0.0 mmol/L (95% CI, −0.3 to 0.2) with placebo, P=0.015 (Nass 2008).

Low Blood Potassium

Hypokalemia (low blood potassium, which can cause muscle weakness and heart-rhythm problems) occurred more often with ipamorelin in the surgical trial (Beck 2014). The mechanism is unknown. Indirect: post-surgical patients receiving vein infusions.

Magnitude: Hypokalemia 12.5% with ipamorelin vs 3.4% with placebo, significance not reported (Beck 2014, figures as tabulated in FDA’s review on the FDA advisory committee page).

Sleep Disruption

Insomnia was reported more often with ipamorelin than with placebo in the surgical trial (Beck 2014). Indirect: hospital patients after bowel surgery sleep poorly regardless, and the infusions differed in route and dose from bedtime injections under the skin.

Magnitude: Insomnia 10.7% with ipamorelin vs 5.2% with placebo, significance not reported (Beck 2014, figures as tabulated in FDA’s review on the FDA advisory committee page).

Fluid Retention, Joint and Muscle Pain, and Heart Failure

GH retains fluid. A meta-analysis tied injected GH in healthy older adults to edema (tissue swelling), arthralgia (joint pain) and carpal tunnel syndrome (wrist nerve compression) (Liu 2007); ibutamoren showed nonsignificant edema and muscle-pain excesses (Nass 2008) and halted a hip-fracture trial over heart failure (Adunsky 2011). Indirect: other compounds.

Magnitude: Ibutamoren 25 mg vs placebo over 12 months: edema 44% vs 27% (P=0.3) and muscle pain 33% vs 9% (P=0.1), neither statistically significant (Nass 2008).

Increased Appetite and Fat Gain

Ghrelin-receptor activation stimulates hunger. Ipamorelin raised food intake and body fat in mice (Lall 2001), and ibutamoren increased appetite in older adults (Nass 2008). A prescribing physician reports less hunger with ipamorelin than older peptides (Huberman Lab episode). Indirect: animals and another compound.

Magnitude: Ibutamoren vs placebo: increased appetite in 67% vs 36%, P=0.02, returning to normal within 3 months in half of ibutamoren users (Nass 2008).

Cancer Promotion via Raised IGF-1

IGF-1 drives cell growth and survival. A meta-analysis linked higher natural IGF-1 to more prostate and premenopausal breast cancer (Renehan 2004), and people with lifelong GH-receptor deficiency (Laron syndrome) rarely develop cancer or diabetes (Guevara-Aguirre 2011). Indirect: the body’s own levels, not ipamorelin.

Magnitude: In that meta-analysis, comparing the 75th with the 25th IGF-1 percentile, prostate cancer OR (odds ratio, the relative odds of disease) 1.49 (95% CI, 1.14 to 1.95) and premenopausal breast cancer OR 1.65 (95% CI, 1.26 to 2.08) (Renehan 2004); people with GH-receptor deficiency had one nonlethal cancer vs a 17% cancer prevalence in relatives without it (Guevara-Aguirre 2011).

Serious Complications in Surgical Patients ⚠️ Conflicted

FDA cites intravenous-trial deaths among its compounding concerns (FDA Category 2 list). Serious events were similar with placebo, but the two ipamorelin-arm deaths, after anastomotic leaks (breakdown of the surgical bowel join), were judged possibly drug-related (Beck 2014; Attia AMA #83). Net: excess risk unproven but not excluded.

Magnitude: Serious adverse events 17.9% with ipamorelin vs 15.5% with placebo; two deaths in the ipamorelin group, with placebo deaths not stated in FDA’s summary (Beck 2014, figures as tabulated in FDA’s review on the FDA advisory committee page).

Speculative 🟨

Immune Reactions and Contamination From Unregulated Product

FDA flags immunogenicity from impure peptide (FDA Category 2 list); black-market samples held an altered ipamorelin analogue (Krug 2018). Anaphylaxis (severe allergic reaction) at high doses is reported anecdotally (Huberman Lab episode). Basis: isolated reports.

Blunted Pituitary Response With Continuous Use

After 15 days of thrice-daily ipamorelin, rats’ GH response to a test dose was marginally reduced (Johansen 1999), hinting at desensitization (a weakening response with repeated use). Basis is animal-only; no human data exist.

Risk-Modifying Factors

  • Genetic variants: No pharmacogenetic data exist for ipamorelin. Inherited cancer-risk variants, such as BRCA1 or BRCA2 (genes that normally repair damaged DNA), may heighten concern about IGF-1-driven cell growth; this is inferred, not studied.
  • Baseline glucose and IGF-1: Prediabetes or insulin resistance raises the stakes of GH’s glucose-raising effect, and a high-normal IGF-1 at baseline leaves little margin before levels exceed the age-adjusted range. Both are inferred from GH-axis physiology.
  • Sex: The IGF-1 associations in a meta-analysis involve prostate cancer in men and premenopausal breast cancer in women (Renehan 2004). No sex-specific ipamorelin safety data exist, and pregnancy and breastfeeding are unstudied.
  • Pre-existing conditions: Active or past cancer, diabetes, heart failure, untreated sleep apnea (repeated breathing pauses in sleep) and diabetic retinopathy (diabetes-related damage to the eye’s blood vessels) are expected to raise risk, inferred from GH-axis effects on cell growth, glucose and fluid.
  • Age: Older adults carry higher baseline cancer, glucose-intolerance and heart-failure risk; ibutamoren’s heart-failure signal arose in elderly hip-fracture patients (Adunsky 2011).

Key Interactions & Contraindications

Documented interactions:

  • None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Glucose-lowering drugs (insulin, metformin, glipizide): GH-driven insulin resistance may weaken glucose control, inferred from GH physiology. Mitigation: fasting glucose and HbA1c (glycated hemoglobin, a three-month blood-sugar average) before starting and after 8–12 weeks.
  • Glucocorticoids (steroid anti-inflammatory drugs: prednisone, dexamethasone): suppress GH release and raise glucose, so they may blunt ipamorelin’s effect while adding hyperglycemia; in rats ipamorelin offset steroid-induced loss of muscle strength (Andersen 2001). Mitigation: glucose monitoring during steroid courses.
  • Somatostatin analogues (drugs that mimic GH’s natural off-switch: octreotide, lanreotide): expected to cancel ipamorelin’s GH release, inferred from opposing pituitary actions. Consequence: loss of effect.
  • Other GH-axis drugs (somatropin, tesamorelin, sermorelin, CJC-1295): additive GH and IGF-1 rise, enlarging glucose, fluid-retention and cancer-related concerns; GHRH analogues amplify ghrelin-receptor signaling. Mitigation: IGF-1 testing at 4–8 weeks when combined.
  • Oral estrogen (estradiol tablets, combined oral contraceptives): reduces the liver’s IGF-1 output, blunting response, inferred from GH physiology; estrogen through the skin has less effect. Mitigation: judge response by IGF-1 rather than dose.
  • Diuretics (drugs that increase urine output: furosemide, hydrochlorothiazide): additive potassium loss, inferred from the hypokalemia signal in the surgical trial (Beck 2014). Mitigation: potassium check at baseline and 4–8 weeks.
  • Testosterone and anabolic steroids (testosterone cypionate, nandrolone): frequent co-use; additive fluid retention and blood-pressure rise, inferred from overlapping effects. Mitigation: blood pressure and edema checks.
  • Over-the-counter high-dose niacin (nicotinic acid): raises blood glucose, adding to GH’s glucose effect, inferred from mechanism. Mitigation: glucose monitoring or avoiding gram-level doses.
  • Supplements that release GH (arginine, ornithine): may modestly add to GH release, inferred from shared pituitary stimulation; the consequence is small additive IGF-1 rise. Mitigation: IGF-1 testing.
  • Ibutamoren (MK-677), sold as a “research chemical”: acts on the same receptor; additive appetite, glucose and fluid effects, inferred from shared mechanism. Mitigation: avoid combining, or test glucose and IGF-1.
  • Carbohydrate-rich meals near dosing: insulin and glucose suppress GH release, blunting the pulse; practitioners separate doses from carbohydrate by 45 minutes to 2 hours (Huberman Lab episode).
  • Alcohol near bedtime: suppresses the nightly GH pulse that bedtime dosing aims to amplify, inferred from sleep physiology. Mitigation: no alcohol within several hours of a bedtime dose.

Populations who should avoid Ipamorelin:

  • Athletes subject to anti-doping testing: ipamorelin is prohibited at all times under category S2 of the World Anti-Doping Agency (WADA) list, per the International Testing Agency (ITA notice; WADA Prohibited List).
  • Active or past cancer: inferred from IGF-1’s growth-promoting action and its association with cancer risk in a meta-analysis (Renehan 2004); no ipamorelin data.
  • Diabetes or prediabetes: inferred from the hyperglycemia excess in the surgical trial (Beck 2014) and ibutamoren’s glucose rise (Nass 2008); no data in people with diabetes.
  • Heart failure: inferred from ibutamoren’s heart-failure signal (Adunsky 2011) and GH-driven fluid retention; no ipamorelin data.
  • Pregnancy and breastfeeding: inferred from hormone-axis stimulation during tightly regulated fetal growth; no human or animal reproductive data exist.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Verified product identity: Batch-specific independent testing for identity (mass spectrometry, a molecular-weight test), sterility and endotoxin (bacterial toxin) reduces the contamination and substituted analogues found in black-market growth peptides (Krug 2018).
  • Low dose ceiling: Staying at 100 micrograms per injection, the ceiling one prescribing physician uses (Huberman Lab episode), rather than forum doses of 200–300 micrograms (Dominikowski 2026), limits flushing and the anaphylaxis he reports at higher doses.
  • Glucose surveillance: Fasting glucose and HbA1c at baseline, 8–12 weeks and every 6 months detect GH-driven hyperglycemia early; stopping when values rise above the laboratory reference range prevents progression to diabetes.
  • IGF-1 ceiling: Testing IGF-1 at 4–8 weeks and reducing or stopping the dose if it exceeds the age- and sex-adjusted laboratory range limits exposure to the high IGF-1 levels associated with cancer in a meta-analysis (Renehan 2004).
  • Potassium check: Testing potassium at baseline and 4–8 weeks, especially with diuretics, detects the hypokalemia seen in the surgical trial (Beck 2014) before it causes weakness or heart-rhythm problems.
  • Symptom-triggered pause: Pausing use at new ankle swelling, hand numbness or tingling, or breathlessness on exertion limits progression of fluid retention, carpal tunnel syndrome and possible heart failure.
  • Cancer screening up to date: Completing age-appropriate cancer screening, including PSA (prostate-specific antigen) testing for men, before starting reduces the risk of stimulating an undetected tumor.
  • Sterile injection technique: Single-use needles, alcohol skin preparation and rotating injection sites prevent injection-site infection, a risk raised because sterility cannot be assumed in informal supply (Dominikowski 2026).
  • Defined cycles: Using 8–12-week cycles with 4–6 weeks off (Dominikowski 2026) caps cumulative IGF-1 exposure and may limit pituitary desensitization.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (timing, cycling, titration) reflect common practice.

  • Practitioner regimen: 100 micrograms injected under the skin at bedtime, described as the effective ceiling by Craig Koniver, a physician whose clinic prescribes peptides (Huberman Lab episode).
  • Self-administration regimen: 200–300 micrograms under the skin two or three times daily, often combined with CJC-1295 without DAC (drug affinity complex, a tag that prolongs action), in 8–12-week cycles, as compiled from bodybuilding sources (Dominikowski 2026).
  • Trial regimens (not wellness use): 0.03 mg/kg infused into a vein twice daily for up to 7 days after bowel surgery (Beck 2014); single infusions of 4.21–140.45 nmol/kg in healthy men (Gobburu 1999).
  • Who popularized it: Peptide-focused physicians such as Koniver promote bedtime dosing (Huberman Lab episode), and bodybuilding forums spread multi-dose regimens and the CJC-1295 pairing (Dominikowski 2026); no professional guideline exists.
  • Alternative approach: Injected GH replaces the hormone directly rather than releasing the body’s own, and a systematic review of its trials in older adults found small body-composition changes with more adverse events (Liu 2007).
  • Time of day: Bedtime dosing aims to amplify the largest natural GH pulse in early deep sleep, with no carbohydrate for 45 minutes to 2 hours beforehand (Huberman Lab episode).
  • Half-life: About 2 hours after an infusion into a vein (Gobburu 1999); the half-life after injection under the skin has not been measured in humans.
  • Single vs split doses: Each injection produces one short GH pulse, so split dosing two or three times daily creates more pulses, while a single bedtime dose aligns with the natural nightly pulse. No trial compares them.
  • Genetic polymorphisms: No gene variant is known to change ipamorelin dosing; dose adjustments rely on the measured IGF-1 response rather than genotype.
  • Sex: Women taking oral estrogen may show a smaller IGF-1 rise and are judged by IGF-1 rather than dose; no sex-specific dosing data exist.
  • Age: Older adults have lower baseline GH but higher glucose and cancer risk, so starting at the low end and adjusting by IGF-1 is the usual approach.
  • Baseline biomarkers: Low-normal IGF-1 for age leaves room for a rise, whereas upper-range values argue against use; baseline HbA1c and fasting glucose set the safety margin.
  • Pre-existing conditions: True GH deficiency from pituitary disease responds poorly because ipamorelin needs a working pituitary; diabetes, cancer history and heart failure shift the balance toward avoidance.

Discontinuation & Cycling

  • Short-term or lifelong: No human data support long-term use; bodybuilding forums use ipamorelin in cycles of weeks to months rather than indefinitely (Dominikowski 2026).
  • Withdrawal effects: None described. With ibutamoren, IGF-1 returned to pretreatment levels within 1 month of stopping, and body-composition gains reversed (Nass 2008).
  • Tapering: No tapering protocol exists or appears necessary, because ipamorelin stimulates rather than replaces the body’s own GH; stopping abruptly is standard practice.
  • Cycling: Bodybuilding protocols use 8–12 weeks on and 4–6 weeks off (Dominikowski 2026); no rationale is given, though repeated dosing slightly blunted the pituitary response in rats (Johansen 1999).

Sourcing and Quality

  • U.S. compounding status: FDA lists ipamorelin acetate in Category 2 for 503B outsourcing facilities (large-scale compounders), and its nomination for 503A pharmacies (prescription-based compounders) was withdrawn (FDA Category 2 list), narrowing regulated supply.
  • Gray-market products: Much supply is sold as “research use only” powder. Seized growth-peptide products contained an unapproved glycine-extended ipamorelin analogue (Krug 2018), and sterility cannot be assumed.
  • Formulation: Ipamorelin acetate is supplied as freeze-dried powder mixed with bacteriostatic water (sterile water with a preservative) for injection under the skin. Nasal versions exist, but nasal absorption was about 20% in rats (Johansen 1998), and oral peptide absorption is minimal.
  • What to look for: A batch-specific certificate of analysis from an independent laboratory showing identity by mass spectrometry, purity of at least 98% by high-performance liquid chromatography (a separation-based purity test), and negative sterility and endotoxin results.
  • Brands and pharmacies: No brand or compounding pharmacy has published independent testing of its ipamorelin, so none can be named on evidence; ConsumerLab and Examine do not cover it.
  • Storage: Once mixed, vials are refrigerated and typically used within about 4 weeks; unmixed powder is stored cold and away from light.

Practical Considerations

  • Time to effect: GH rises within an hour of a dose (Gobburu 1999). Body-composition changes with ibutamoren emerged over 6–12 months (Nass 2008), so any ipamorelin effect would likely take months; sleep effects are reported anecdotally within weeks.
  • Common pitfalls: Judging efficacy by flushing, stacking several GH-axis peptides without IGF-1 checks, buying unverified “research” vials, dosing right after carbohydrate-rich meals, and assuming the compound is legal for tested athletes.
  • Regulatory status (FDA): Ipamorelin is an unapproved investigational peptide. Ipamorelin acetate has sat in FDA’s Category 2 for outsourcing facilities since September 29, 2023, and the FDA page, current as of April 22, 2026, still lists it (FDA Category 2 list).
  • Advisory committee: An FDA advisory committee (FDA advisory committee page) voted in October 2024 against adding it to the 503A list, as reported by the Alliance for Pharmacy Compounding, whose members earn from compounding (A4PC news report; FDA minutes not posted as a web page).
  • Conflicting media reports: A 2026 article in the American Journal of Managed Care states ipamorelin was “removed from the Category 2 list” (AJMC report); FDA’s own page shows only the 503A nomination withdrawn and the 503B entry still in place.
  • Anti-doping: Ipamorelin is prohibited in and out of competition under WADA category S2, and a cyclist was provisionally suspended for it in August 2026 (ITA notice).
  • Cost and access: Cost is modest, but legitimate access is difficult because regulated compounding is restricted. No insurer covers ipamorelin or injected GH for aging, so payer incentives are unlikely to bias this evidence base.

Interaction with Foundational Habits

  • Sleep: Direction: intended to be potentiating, but uncertain. Bedtime dosing aims to amplify the GH pulse of early deep sleep; ibutamoren deepened sleep (Copinschi 1997), yet insomnia rose with ipamorelin in the surgical trial (Beck 2014). Consistent sleep timing and tracking sleep before and during use clarify individual response.
  • Nutrition: Direction: blunting by meals. Insulin and glucose suppress GH release, so practitioners separate doses from carbohydrate by 45 minutes to 2 hours (Huberman Lab episode). Adequate protein is needed for any lean-mass gain, and ghrelin-receptor activation may raise appetite and total intake.
  • Exercise: Direction: indirect. Exercise itself releases GH, and resistance training is likely required for lean mass to become strength: ibutamoren raised lean mass in older adults without strength or function gains (Nass 2008). Some users dose after training, though no study compares timing.
  • Stress management: Direction: none expected. Unlike GHRP-2 and GHRP-6, ipamorelin did not raise ACTH or cortisol in pigs (Raun 1998). Chronic stress and high cortisol suppress GH release and may blunt the response, so stress reduction supports rather than interacts with use.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a blood panel records IGF-1, fasting glucose, HbA1c and potassium, establishing personal reference points and screening for conditions that argue against use, such as undiagnosed diabetes. Men add a PSA test, and everyone brings age-appropriate cancer screening up to date before the first injection.

Ongoing monitoring: Retesting at 4–8 weeks, at the end of each 8–12-week cycle, then every 6 months during continued use captures the IGF-1 response and early glucose or potassium changes. A body-composition scan at baseline and after 6 months shows whether lean mass changed. No trial defines this schedule; it follows common practice. Success means an IGF-1 rise within the age-adjusted range with stable glucose, plus measurable gains in lean mass or sleep.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
IGF-1 Age- and sex-specific laboratory range (standard reference range) Expected to rise; safety check, as values above range reduce or stop use Insulin-like growth factor 1; same laboratory each time, since assays differ; track change from own baseline
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: a rise reduces or stops use Fast 8 hours or more; pair with HbA1c
HbA1c 4.0–5.6% (standard reference range) Safety check: a rise reduces or stops use Glycated hemoglobin, a three-month blood-sugar average; no fasting needed; anemia distorts it
Potassium 3.5–5.0 mmol/L (standard reference range) Safety check: low values pause use Hypokalemia was more frequent in the ipamorelin surgical trial (Beck 2014); check closely with diuretics
PSA (men) Age-specific laboratory range (standard reference range) Safety check: a rise stops use pending evaluation Prostate-specific antigen; avoid ejaculation and cycling for 48 hours before testing
Lean mass No established target; track change from own baseline Expected to change Measured by DXA (dual-energy X-ray absorptiometry, a low-dose body scan); same scanner each time

Qualitative markers:

  • Sleep depth and continuity
  • Recovery after training
  • Hunger between meals
  • Ankle swelling, hand numbness or joint aches

Emerging Research

  • Trifecta Research Study (NCT07717866): An observational study of 52 special-operations veterans receiving ibogaine and 5-MeO-DMT (psychedelic compounds), magnetic brain stimulation and hormone “supplementation” that includes ipamorelin; completion estimated November 2026. A positive result could not isolate ipamorelin’s share, and a null result would leave this review’s conclusion unchanged.
  • Unreported dose-finding trial (NCT01280344): 320 bowel-surgery patients randomized to three intravenous doses or placebo; completed May 2014, no results posted. Published results showing a clean safety profile would ease the glucose and potassium concerns; confirmed dose-related signals would strengthen them.
  • Direct trial gap: No randomized trial of under-the-skin ipamorelin in healthy or older adults exists. A 6–12-month trial measuring lean mass, strength, sleep, glucose and IGF-1, modeled on ibutamoren’s two-year trial (Nass 2008), would be the first direct test of the longevity rationale.
  • Evidence that could weaken the case: People with lifelong low GH signaling show little cancer or diabetes (Guevara-Aguirre 2011), and a meta-analysis found higher IGF-1 tracks with some cancers (Renehan 2004); further cohort work could undercut the premise that raising IGF-1 supports longevity.
  • Evidence that could strengthen the case: Ipamorelin partly offset chemotherapy-induced weight loss in ferrets (Lu 2024, Helsinn co-authors), and ibutamoren raised lean mass in older adults (Nass 2008); a human trial showing functional gains without glucose harm would strengthen the case for selective GH release.

Conclusion

Ipamorelin is a small lab-made protein fragment that prompts the pituitary gland to release the body’s own growth hormone in short bursts. Health-focused adults value it because, unlike older compounds of its kind, it did not raise stress hormones in animal studies, and because it works with the body’s natural rhythm rather than replacing the hormone outright.

The case for it rests mostly on how it works rather than on what it has been shown to do in people. Its hoped-for benefits for muscle, fat, sleep and bone are drawn from animal studies and from a related oral drug and injected growth hormone, which modestly increased lean tissue without making older adults stronger. The one meaningful human trial of ipamorelin itself, in patients recovering from bowel surgery, did not show a clear benefit.

The risks are better grounded in biology than in direct measurement: higher blood sugar, low potassium, poorer sleep, fluid retention and joint aches, and a long-term question about cancer, since the growth signal it raises also feeds cell growth. Product quality adds uncertainty, because much of the supply is unregulated.

The evidence base is small and old, and much of it was produced by the companies that developed or later tested the compound, while its most vocal supporters include physicians who prescribe it. For this audience, ipamorelin remains a plausible but unproven experiment, with benefits inferred and risks only partly measured.

Top - Benefits - Risks - Protocol